Recently, Zhou et al. reported that HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with ccRCC, which is also significantly associated with TILs and suggests that the PFS and OS of tumor patients can be influenced by the tumor immune microenvironment [14]. The gene discussed is HHLA2; the disease is neoplasm.